Database and Biobank of Patients With Hypersensitivity Pneumonitis
Pulmonary Fibrosis Biobank - Hypersensitivity Pneumonitis
Nils Hoyer
50 participants
Sep 18, 2022
OBSERVATIONAL
Conditions
Summary
Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data. The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016. Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.
Eligibility
Inclusion Criteria3
- Diagnosis of HP at an MDT conference according to the current international guidelines
- Age of 18 years or older
- The patients must be capable of giving informed consent
Exclusion Criteria1
- \- Unable to sign informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05549635